All In Biotech

NDA 018461 · Baxter Hlthcare

Lidocaine Hydrochloride 0.8% and Dextrose 5% In Plastic Container

Lidocaine Hydrochloride · Injection

Last checked: Nov 19, 2026Latest source record: Feb 7, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Apr 22, 1981

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,569

373 Phase 3, 196 recruiting

FAERS reports

7,041

4,863 serious, 583 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 20, 2026.

INDICATIONS AND USAGE Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction.

Mechanism: Mechanism of Action Lidocaine hydrochloride exerts an antiarrhythmic effect by increasing the electrical stimulation threshold of the ventricle during diastole. In usual therapeutic doses, lidocaine hydrochloride produces no change in myocardial contractility, in systemic arterial pressure, or in absolute refractory period. Central nervous system adverse reactions become apparent with increasing venous plasma levels above 6.0 μg free base per mL.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 22, 1981 Original approval · Type 3 - New Dosage Form
4 products under this application
  • LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER · LIDOCAINE HYDROCHLORIDE 800MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER · LIDOCAINE HYDROCHLORIDE 200MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER · LIDOCAINE HYDROCHLORIDE 400MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER · LIDOCAINE HYDROCHLORIDE 100MG/100ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.

All 2,569 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infusion site pain792
  • drug ineffective575
  • nausea517
  • infusion site erythema494
  • headache464
  • dyspnoea449
  • diarrhoea445
  • off label use430
  • fatigue390
  • pain374
  • infusion site swelling345
  • dizziness325

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200435
200518
20069
20079
200828
200951
201050
201164
201285
201390
201457
2015166
2016121
2017139
2018171
2019168
2020199
2021324
2022593
2023990
20241,457
20251,368
2026849

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03).

  • Current · updated Nov 18, 2026

    Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,282 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Lidocaine Hydrochloride 0.2% and Dextrose 5% In Plastic Container, Lidocaine Hydrochloride 0.4% and Dextrose 5% In Plastic Container, Lidocaine Hydrochloride 0.1% and Dextrose 5% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.